Schrödinger Q1 total revenue up 51% to $48.7M; net loss widens to $34.5M

Schrodinger, Inc.

2023-Q1 EPS reported -$0.48 revenue$48,663,000

Software revenue $33.1M (+26% YoY); drug discovery revenue $15.6M (+169% YoY).
Net loss of $34.5M compared to $0.5M loss in Q1 2021.
Maintains full-year 2022 total revenue guidance of $161M-$181M.
Cash, equivalents, and marketable securities of ~$529M; MALT1 IND on track for H1 2022.
Software gross margin 77%; operating expenses $56.6M, up 41% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.